EZH2 and cancer: While the role of somatic PRC2 dysfunction in cancer is well established, the connection between germline mutations in PRC2 subunits and NDDs only began to emerge in 2012, with the discovery of de novo EZH2 variants as one of the first causes of an OGID syndrome [64,65].